Anbio Biotechnology (NNNN) 시세

Its just you and me bro...🥳

NNNN...$5.67...🥳...Scaling in...will add up or down...

$NNNN : Anbio IPOing

Now at $5.50


https://www.anbio.com/about

Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. At Anbio Biotechnology, our extensive portfolio comprises an array of IVD products designed to cater to diverse diagnostic needs. Our comprehensive range encompasses solutions for various applications, including over-the-counter utilization, point-of-care settings, and laboratory applications. Our IVD products are designed to detect a wide range of biomarkers associated with critical medical domains. These domains encompass infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes.


********************************************************************************

Frankfurt am Main, Germany, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Anbio Biotechnology (the “Company” or “Anbio”), a global diagnostic company dedicated to the advancement of medical technology and the provision of in vitro diagnostics products, today announced the pricing of its initial public offering (the “Offering”) of 1,600,000 Class A ordinary shares (“the Class A Ordinary Shares”) at a public offering price of US$5.00 per Class A Ordinary Share. The Class A Ordinary Shares have been approved for listing on the Nasdaq Global Market and are expected to commence trading on February 19, 2025 under the ticker symbol “NNNN.”

The Company expects to receive aggregate gross proceeds of US$8 million from the Offering, before deducting underwriting discounts and other related expenses. The Offering is expected to close on or about February 20, 2025, subject to the satisfaction of customary closing conditions.

Proceeds from the Offering will be used for expansion of sales and distribution network in the strategically selected markets, research and development, and working capital and general corporate matters.

The Offering is being conducted on a firm commitment basis. AC Sunshine Securities LLC is acting as the underwriter for the Offering (the “Underwriter”). Ortoli Rosenstadt LLP is acting as U.S. counsel to the Company, and Focus Law is acting as U.S. counsel to the Underwriter in connection with the Offering.

A registration statement on Form F-1 relating to the Offering was filed with the U.S. Securities and Exchange Commission (the “SEC”) (File Number: 333-284106), as amended, and was declared effective by the SEC on February 18, 2025. The Offering is being made only by means of a prospectus, forming a part of the registration statement. Copies of the final prospectus relating to the Offering, when available, may be obtained from AC Sunshine Securities LLC by email at prospectus@acsunshine.com, by standard mail to 200 E. Robinson Street, Suite 295, Orlando, FL 32801, or by telephone at +1 (689)-689-9686. In addition, copies of the final prospectus relating to the Offering, when available, may be obtained via the SEC's website at www.sec.gov.

Before you invest, you should read the prospectus and other documents the Company has filed or will file with the SEC for more information about the Company and the Offering. This press release does not constitute an offer to sell, or the solicitation of an offer to buy any of the Company’s securities, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from registration, nor shall there be any offer, solicitation or sale of any of the Company’s securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.